

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application for:

Kin-Ping WONG

Serial No.: 10/021,820

Filing Date: December 13, 2001

For: COMPOSITIONS CONTAINING AN
ACTIVE FRACTION ISOLATED
FROM TRICHOLOMA
CONGLOBATUM AND METHODS OF
USE

Examiner: Not Yet Assigned

Group Art Unit: 1619



INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO-1449b are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the new patent application submitted herewith (37 C.F.R. § 1.97(a)).
- ☐ Within three months of the application filing date or before receipt of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☒ Before the mailing date of the first Office Action on the merits. In the event, however that an Office Action has crossed in the mail with this Information Disclosure

Statement, the Commissioner is hereby authorized to charge Deposit Account No. 50-1189 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).

- ☐ After receipt of a first Office Action on the merits but before a final Office Action or Notice of Allowance. A fee is required. The Commissioner is hereby authorized to charge Deposit Account No. 50-1189 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).
- ☐ After receipt of a final Office Action or Notice of Allowance, but before payment of the issue fee. Accordingly, a Certification under 37 C.F.R. § 1.97(c) is provided herein. The Commissioner is hereby authorized to charge Deposit Account No. 50-1189 for any fees required pursuant to 37 C.F.R. §§ 1.17(p) or 1.17(i)(1).

The undersigned certifies that:

- ☐ Each item of information contained in the Information Disclosure Statement was first cited in any communication mailed from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication mailed from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

This Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols,

results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the U.S. Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 50-1178** referencing 23888-7016. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: June 17, 2002

By: Antoinette F. Konski
Antoinette F. Konski
Registration No. 34,202

McCutchen Doyle Brown & Enersen LLP
Three Embarcadero Center, Suite 1800
San Francisco, California 94111-4067
Telephone: (650) 849-4950
Facsimile: (650) 849-4800

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number 10/021,820

Filing Date December 13, 2001

First Named Inventor Kin-Ping WONG

Art Unit 1619

Examiner Name Not Yet Assigned

Attorney Docket Number AN 2004.00

 JUN 26 2002
TECH CENTER 1600/2990

RECEIVED

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T ²
	1	ACHEN, M.G. and STACKER, S.A. "The Vascular Endothelial Growth Factor Family; Proteins Which Guide the Development of the Vasculature" <i>Int. J. Exp. Path.</i> (1998) 79 :255-265	
	2	AUGUSTIN, H.G. et al. "Ovarian Angiogenesis Phenotypic Characterization of Endothelial Cells in a Physiological Model of Blood Vessel Growth and Regression" <i>Am. J. Pathol.</i> (1995) 147 (2):339-351	
	3	BITTER, T. and MUIR, H.M. "A Modified Uronic Acid Carbazole Reaction" <i>Anal. Chem.</i> (1962) 4 :330-334	
	4	BRADFORD, M.M. "A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding" <i>Anal. Biochem.</i> (1976) 72 :248-254	
	5	BROOKS, P.C. et al. "Requirement of Vascular Integrin $\alpha_v\beta_3$ for Angiogenesis" <i>Science</i> (1994) 264 :569-571	
	6	BROOKS, P.C. et al. "Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin $\alpha_v\beta_3$ " <i>Cell</i> (May, 1996) 85 :683-693	
	7	BUSSOLINO, F., et al. "Molecular Mechanisms of Blood Vessel Formation" <i>Trends in Biochem Sci</i> (1997) 22 (7):251-256	
	8	CONNOLLY, D.T. et al. "Determination of the Number of Endothelial Cells in Culture Using an Acid Phosphatase Assay" <i>Anal. Biochem.</i> (1986) 152 :136-140	
	9	DEVALARAJA, M. and RICHMOND, A. "Multiple Chemotactic Factors: Fine Control or Redundancy?" <i>Trends in Pharmacol. Sci.</i> (1999) 20 (4):151-156	
	10	DUBOIS, M. et al. "Colorimetric Method for Determination of Sugars and Related Substances" <i>Analyt. Chem.</i> (1956) 28 :350-356	
	11	FOLKMAN, J. "Angiogenesis in Cancer, Vasular, Rheumatoid and Other Diseases" <i>Nature Med.</i> (1995) 1 (1):27-31	
	12	FOLKMAN, J. and D'AMORE, P.A. "Blood Vessel Formation: What is its Molecular Basis?" <i>Cell</i> (1996) 87 :1153-1155	
	13	GOODGER, A.M. (MacPherson) and ROGERS, P.A.W. "Blood Vessel Growth in the Endometrium" <i>Microcirculation</i> (1995) 2 (4):329-343	
	14	HANAHAN, D. "Signaling Vascular Morphogenesis and Maintenance" <i>Science</i> (1997) 277 :48-50	
	15	HEALY, D.L. et al. "Angiogenesis: A New Theory for Endometriosis" <i>Hum. Reprod. Update</i> (1998) 4 (5):736-740	
	16	KOCH, A.E. et al. "Angiogenesis Mediated by Soluble Forms of E-Selectin and Vascular Cell Adhesion Molecule-1" <i>Nature</i> (1995) 376 :517-519	
	17	MAISONPIERRE, P.C. et al. "Angiopoietin-2, a Natural Antagonist for Tie2 that Disrupts in vivo Angiogenesis" <i>Science</i> (1997) 277 :55-60	
	18	MIGNATTI, P. and RIFKIN, D.B. "Plasminogen Activators and Matrix Metalloproteinases in Angiogenesis" <i>Enzyme Protein</i> (1996) 49 :117-137	
	19	NGUYEN, M. et al. "Quantitation of Angiogenesis and Antiangiogenesis in the Chick Embryo Chorioallantoic Membrane" <i>Microvas. Res.</i> (1994) 47 :31-40	
	20	O'REILLY, M.S. et al. "Angiostatin: A Novel Angiogenesis Inhibitor that Mediates the Suppression of Metastases by a Lewis Lung Carcinoma" <i>Cell</i> (1994) 79 (2):315-328	
	21	O'REILLY, M.S. et al. "Endostatin: An Endogenous Inhibitor of Angiogenesis and Tumor Growth" <i>Cell</i> (1997) 88 (2):277-285	



OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner's
Signature

Date
Considered

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231